AN ANALYSIS OF THE RELATIONSHIP OF CLINICAL ACTIVITY TO BASELINE EGFR STATUS, PDL1 EXPRESSION AND PRIOR TREATMENT HISTORY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) FOLLOWING PD-L1 BLOCKADE WITH MPDL3280A (ANTI-PDL1)

被引：0

作者：

Horn, Leora ^{[1
]}

Herbst, Roy S. ^{[2
]}

Spigel, David ^{[3
]}

Gettinger, Scott N. ^{[2
]}

Gordon, Michael S. ^{[4
]}

Hollebecque, Antoine ^{[5
]}

Gandhi, Leena ^{[6
]}

Felip, Enriqueta ^{[7
]}

Heist, Rebecca ^{[8
]}

Mokatrin, Ahmad ^{[9
]}

Kowanetz, Marcin ^{[9
]}

Waterkamp, Daniel ^{[9
]}

Fine, Gregg ^{[9
]}

Soria, Jean-Charles ^{[5
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[2] Yale Univ, Sch Med, New Haven, CT 06520 USA

[3] Tennessee Oncol Pllc, Sarah Cannon Res Inst, Franklin, TN USA

[4] Pinnacle Oncol Hematol, Scottsdale, AZ USA

[5] Inst Gustave Roussy, Villejuif, France

[6] Harvard Univ, Sch Med, Dana Farber Canc Inst, Cambridge, MA 02138 USA

[7] Vall Dhebron Univ Hosp, Barcelona, Spain

[8] Massachusetts Gen Hosp, Boston, MA 02114 USA

[9] Genentech Inc, San Francisco, CA USA

来源：

关键词：

PD-L1; metastatic; PD-1; immunotherapy;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MO18.01

引用

页码：S364 / S364

页数：1